Literature DB >> 20303939

Effect of cyclic AMP-elevating agents on airway ciliary beat frequency in central and lateral airways in rat precision-cut lung slices.

Andrea Wohlsen1, Andrea Hirrle, Hermann Tenor, Degenhard Marx, Rolf Beume.   

Abstract

In patients with chronic obstructive pulmonary disease (COPD), mucociliary clearance of the respiratory tract is impaired due to enhanced mucus secretion and deterioration of normal ciliary activity. We investigated the effects of cyclic AMP-elevating agents with a different mode of action on ciliary beat frequency (CBF) in rat large central and small lateral airways by comparing the phosphodiesterase-4 (PDE4) inhibitors rolipram and roflumilast to the beta(2)-adrenoceptor agonist terbutaline and the adenylyl cyclase activator forskolin. Rat precision-cut lung slices were prepared and effects of cyclic AMP-elevating agents on CBF were assessed for up to 4h. In central airways a time- and concentration-dependent increase in CBF was seen for roflumilast (59+/-4%, 1microM, 60min), rolipram (55+/-4%, 1microM, 60min), terbutaline (64+/-8%, 10microM, 60min) and forskolin (55+/-8%, 100microM, 60min). Only roflumilast and rolipram increased CBF in lateral airways, with a similar time course and maximum efficacy (roflumilast 48+/-5%, rolipram 54+/-2%). Incubation of lateral airways with terbutaline (10microM, +11%) or forskolin (100microM, +1%) had negligible effects. As a major novel finding this study reveals that PDE4 inhibitors increased CBF in central as well as in lateral airways, while terbutaline and forskolin affected CBF in proximal airways only.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20303939     DOI: 10.1016/j.ejphar.2010.03.005

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  6 in total

1.  Roflumilast N-oxide, a PDE4 inhibitor, improves cilia motility and ciliated human bronchial epithelial cells compromised by cigarette smoke in vitro.

Authors:  J Milara; M Armengot; P Bañuls; H Tenor; Rolf Beume; E Artigues; J Cortijo
Journal:  Br J Pharmacol       Date:  2012-08       Impact factor: 8.739

Review 2.  Roflumilast: in chronic obstructive pulmonary disease.

Authors:  Mark Sanford
Journal:  Drugs       Date:  2010-08-20       Impact factor: 9.546

Review 3.  Exploring lung physiology in health and disease with lung slices.

Authors:  Michael J Sanderson
Journal:  Pulm Pharmacol Ther       Date:  2011-05-12       Impact factor: 3.410

Review 4.  Applications and Approaches for Three-Dimensional Precision-Cut Lung Slices. Disease Modeling and Drug Discovery.

Authors:  Hani N Alsafadi; Franziska E Uhl; Ricardo H Pineda; Kolene E Bailey; Mauricio Rojas; Darcy E Wagner; Melanie Königshoff
Journal:  Am J Respir Cell Mol Biol       Date:  2020-06       Impact factor: 6.914

Review 5.  Respiratory Cilia as a Therapeutic Target of Phosphodiesterase Inhibitors.

Authors:  Marta Joskova; Juraj Mokry; Sona Franova
Journal:  Front Pharmacol       Date:  2020-05-06       Impact factor: 5.810

6.  Roflumilast Attenuates Doxorubicin-Induced Cardiotoxicity by Targeting Inflammation and Cellular Senescence in Cardiomyocytes Mediated by SIRT1.

Authors:  Sheng Zhang; Peng Wu; Jiabao Liu; Yingqiang Du; Zhijian Yang
Journal:  Drug Des Devel Ther       Date:  2021-01-11       Impact factor: 4.162

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.